Financial Services » Investing & Securities | Cellular Biomedicine Group Inc.

Cellular Biomedicine Group Inc. | Income Statement

Fiscal year is January-December. All values USD Thousands.
2013
2014
2015
2016
2017
2018
Sales/Revenue
4,069.50
564.40
2,505.40
627.90
336.80
224.40
Cost of Goods Sold (COGS) incl. D&A
1,604.70
1,403.70
2,927.70
3,495.40
3,148.20
5,185.30
Gross Income
2,464.80
839.40
422.20
2,867.50
2,811.40
4,960.90
SG&A Expense
11,332.40
10,175.30
20,303.30
20,936.10
24,765.20
32,630.50
EBIT
8,867.60
11,014.60
20,725.50
23,803.60
27,576.60
37,591.40
Unusual Expense
4,259.00
1,427.80
123.40
4,611.70
-
2,914.30
Non Operating Income/Expense
71.50
72.00
630.40
54.10
122.40
1,172.90
Interest Expense
257.80
-
-
-
-
-
Pretax Income
13,452.60
12,355.50
20,176.30
28,204.30
25,487.90
38,940.50
Income Tax
344.40
-
728.60
4.10
2.50
5
Consolidated Net Income
13,797.00
12,355.50
19,447.70
28,208.40
25,490.30
38,945.50
Net Income
13,797.00
12,355.50
19,447.70
28,208.40
25,490.30
38,945.50
Net Income After Extraordinaries
13,797.00
9,236.30
19,447.70
28,208.40
25,490.30
38,945.50
Net Income Available to Common
13,797.00
15,474.60
19,447.70
28,208.40
25,490.30
38,945.50
EPS (Basic)
2.38
1.79
1.70
2.09
1.78
2.20
Basic Shares Outstanding
5,792.90
8,627.10
11,472.30
13,507.40
14,345.60
17,741.10
EPS (Diluted)
2.38
1.79
1.70
2.09
1.78
2.20
Diluted Shares Outstanding
5,792.90
8,627.10
11,472.30
13,507.40
14,345.60
17,741.10
EBITDA
8,026.40
9,824.10
18,630.90
21,168.60
24,590.60
32,541.90
Non-Operating Interest Income
3.20
15.00
42.20
78.90
133.60
392.30

About Cellular Biomedicine Group

View Profile
Address
1345 Avenue of Americas
New York New York 10105
United States
Employees -
Website http://www.cellbiomedgroup.com
Updated 07/08/2019
Cellular Biomedicine Group, Inc. is a clinical stage biopharmaceutical company, which engages in the development of new treatments for cancerous and degenerative diseases utilizing proprietary cell-based technologies. Its technology includes immune system therapy for treatment of cancer indications and human adipose-derived mesenchymal progenitor cells (haMPC) for treatment of joint and autoimmune diseases The company was founded in 2009 and is headquartered in Cupertino, CA. .

StatInvestor

Privacy Policy
Feedback

© 2024 StatInvestor All Rights Reserved.